## Diederik De Cock

## List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/5103681/diederik-de-cock-publications-by-year.pdf

**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

36 13 1,344 73 h-index g-index citations papers 98 2,265 4.16 3.1 L-index avg, IF ext. papers ext. citations

#	Paper	IF	Citations
73	Psychological stress in rheumatoid arthritis: a systematic scoping review <i>Seminars in Arthritis and Rheumatism</i> , <b>2022</b> , 55, 152014	5.3	1
72	The perception of stakeholders on the applicability of nurse-led clinics in the management of rheumatoid arthritis. <i>Rheumatology Advances in Practice</i> , <b>2021</b> , 5, ii45-ii52	1.1	O
71	Does Including Pain, Fatigue, and Physical Function When Assessing Patients with Early Rheumatoid Arthritis Provide a Comprehensive Picture of Disease Burden?. <i>Journal of Rheumatology</i> , <b>2021</b> , 48, 174-178	4.1	4
70	Treatment response and several patient-reported outcomes are early determinants of future self-efficacy in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , <b>2021</b> , 23, 269	5.7	О
69	Belgian rheumatologists' preferences regarding measures of disease activity in patients with rheumatoid arthritis: results from a mixed-methods study. <i>Rheumatology International</i> , <b>2021</b> , 1	3.6	
68	Having a co-morbidity predicts worse outcome in early rheumatoid arthritis despite intensive treatment: a post hoc evaluation of the pragmatic randomized controlled CareRA trial. <i>Rheumatology</i> , <b>2021</b> , 60, 3699-3708	3.9	2
67	Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	5
66	AB0109 VALIDATION OF SEPARATE PATIENT-REPORTED, CLINICAL AND LABORATORY FACTOR SCORES AS REPRESENTATION OF DISEASE BURDEN IN A POPULATION WITH ESTABLISHED RHEUMATOID ARTHRITIS. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 1083.1-1083	2.4	
65	POS0300 DOES COGNITIVE BEHAVIORAL THERAPY IMPROVE PSYCHOSOCIAL OUTCOME IN RHEUMATOID ARTHRITIS: A SYSTEMATIC LITERATURE REVIEW. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 375-375	2.4	
64	POS1433 IMPACT OF RHEUMATOID ARTHRITIS ON STRESS: A SYSTEMATIC SCOPING REVIEW. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 1001.1-1001	2.4	
63	Short-term glucocorticoids reduce risk of chronic NSAID and analgesic use in early methotrexate-treated rheumatoid arthritis patients with favourable prognosis: subanalysis of the CareRA randomised controlled trial. <i>RMD Open</i> , <b>2021</b> , 7,	5.9	2
62	POS0266-HPR PATIENT-PERCEIVED ASPECTS OF RA FLARE EVOLVE OVER TIME, AS REFLECTED BY THE FLARE-RA QUESTIONNAIRE: POST-HOC ANALYSIS OF TAPERA. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 356.1-356	2.4	1
61	POS0503 THE DISCORDANCE BETWEEN PATIENT-REPORTED AND CLINICAL/BIOLOGICAL OUTCOMES COULD HELP IN PREDICTING FUTURE DISEASE IMPACT IN PATIENTS WITH RHEUMATOID ARTHRITIS. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 484.1-484	2.4	1
60	POS0616 LONG-TERM EFFECTIVENESS AFTER MULTIPLE CYCLES WITH RITUXIMAB FOLLOWING AN ON-FLARE RETREATMENT STRATEGY IN PATIENTS WITH RHEUMATOID ARTHRITIS. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 545-546	2.4	
59	POS1203 EFFECT OF THE COVID19 PANDEMIC ON RHEUMATOLOGIST PRESCRIPTION BEHAVIOUR OF NEW ADVANCED THERAPY: DATA OF THE TARDIS-RA REGISTRY, A NATIONWIDE BELGIAN BIOLOGIC REGISTRY. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 884.1-884	2.4	
58	POS0093 HETEROGENEITY IN ADVERSE EVENT ASSESSMENT BETWEEN COUNTRIES PARTICIPATING IN AN INTERNATIONAL COLLABORATION OF REGISTRIES OF RHEUMATOID ARTHRITIS PATIENTS USING JANUS KINASE INHIBITORS (THE JAK-POT STUDY). Annals of the	2.4	
57	Rheumatic Diseases, 2021, 80, 256-257 POS0181 HOW FIT ARE THE SOCIAL SUPPORT INSTRUMENTS USED IN RMDS: A SYSTEMATIC REVIEW OF VALIDATION STUDIES. Annals of the Rheumatic Diseases, 2021, 80, 304.1-304	2.4	

56	Comorbidity burden in the first three years after diagnosis in patients with rheumatoid arthritis, psoriatic arthritis or spondyloarthritis: a general practice registry-based study. <i>RMD Open</i> , <b>2021</b> , 7,	5.9	2
55	Response to: 'Correspondence on 'Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial" by Jain and Dhir. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	Ο
54	Comment on: what is the best treatment for early rheumatoid arthritis?. Rheumatology, 2021, 60, e177	-e31 <i>3</i> 78	
53	EULAR recommendations for a core data set for pregnancy registries in rheumatology. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 49-56	2.4	16
52	The ideal mHealth-application for rheumatoid arthritis: qualitative findings from stakeholder focus groups. <i>BMC Musculoskeletal Disorders</i> , <b>2021</b> , 22, 746	2.8	1
51	Tapering of Etanercept is feasible in patients with Rheumatoid Arthritis in sustained remission: a pragmatic randomized controlled trial. <i>Scandinavian Journal of Rheumatology</i> , <b>2021</b> , 1-11	1.9	3
50	One in five patients with rapidly and persistently controlled early rheumatoid arthritis report poor well-being after 1 year of treatment. <i>RMD Open</i> , <b>2020</b> , 6,	5.9	8
49	Two-year cost-effectiveness of different COBRA-like intensive remission induction schemes in early rheumatoid arthritis: a piggyback study on the pragmatic randomised controlled CareRA trial. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 556-565	2.4	6
48	Effectiveness of maintenance therapy with methotrexate compared with leflunomide for patients with RA having achieved disease control with both these drugs: results of a predefined sub-analysis of CareRA, a pragmatic RCT. <i>Clinical Rheumatology</i> , <b>2020</b> , 39, 2593-2601	3.9	
47	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 685-6	9 <del>3</del> .4	851
46	Correspondence on 'EULAR recommendations for a core data set for pregnancy registries in rheumatology'. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> ,	2.4	1
45	OP0231 COMPARATIVE EFFECTIVENESS OF JAK-INHIBITORS, TNF-INHIBITORS, ABATACEPT AND IL-6 INHIBITORS IN AN INTERNATIONAL COLLABORATION OF REGISTERS OF RHEUMATOID ARTHRITIS PATIENTS (THE LIAK-POTLSTUDY). Annals of the Rheumatic Diseases, 2020, 79, 146-147	2.4	1
44	THU0200 THE CHOICE OF BDMARD OR TSDMARD AS FIRST LINE THERAPY: DATA OF THE TARDIS-RA REGISTRY, A NATIONWIDE BELGIAN BIOLOGIC REGISTRY. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 322-322	2.4	
43	FRI0023 TREATING EARLY AND INTENSIVELY IS ASSOCIATED WITH LOWER FATIGUE LEVELS ON THE LONG TERM, EVEN IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS CONSIDERED TO HAVE A FAVOURABLE RISK PROFILE. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 583.2-584	2.4	
42	THU0214 LONG-TERM EFFECTIVENESS OF METHOTREXATE WITH STEP DOWN GLUCOCORTICOID BRIDGING (COBRA SLIM) VERSUS OTHER CONVENTIONAL DMARD REGIMENS AS INITIAL RA THERAPY: 5-YEAR OUTCOMES OF THE CARERA TRIAL <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 332	2.4 -333	1
41	FRI0035 THE CHALLENGE OF ASSESSING WELL-BEING IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 591.2-591	2.4	
40	SAT0028 THE FLARE-RA QUESTIONNAIRE CAN PREDICT FLARES IN PATIENTS WITH ESTABLISHED RHEUMATOID ARTHRITIS PARTICIPATING IN THE TAPERA TRIAL. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 944.3-944	2.4	1
39	FRI0566 THE FLARE-RA QUESTIONNAIRE CAN IDENTIFY OMERACT FLARES IN PATIENTS WITH RHEUMATOID ARTHRITIS INCLUDED IN THE TAPERA TRIAL. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 885.1-886	2.4	

The rheumatoid arthritis patient global assessment: improve it or lose it!. Rheumatology, 2020, 59, 923-924 38 3 A systematic review on the effect of DMARDs on fertility in rheumatoid arthritis. Seminars in 37 5.3 Arthritis and Rheumatism, 2020, 50, 873-878 Response to Unmet needs in the treatment of rheumatoid arthritis. An observational study and a 36 5.3 real-life experience from a single university center. Seminars in Arthritis and Rheumatism, 2020, 50, e6 The perspective of patients with early rheumatoid arthritis on the journey from symptom onset 1.1 35 4 until referral to a rheumatologist. Rheumatology Advances in Practice, 2019, 3, rkz035 Effectiveness of different combinations of DMARDs and glucocorticoid bridging in early 18 34 3.9 rheumatoid arthritis: two-year results of CareRA. Rheumatology, 2019, 58, 2284-2294 Methotrexate persistence and adverse drug reactions in patients with juvenile idiopathic arthritis. 6 3.9 33 Rheumatology, **2019**, Patient-Reported Outcome Data From an Early Rheumatoid Arthritis Trial: Opportunities for 8 32 4.7 Broadening the Scope of Treating to Target. Arthritis Care and Research, 2019, 71, 1566-1575 Use and effectiveness of rituximab in children and young people with juvenile idiopathic arthritis in 31 3.9 13 a cohort study in the United Kingdom. Rheumatology, 2019, 58, 331-335 Modifiable correlates of illness perceptions in adults with chronic somatic conditions: A systematic 2 9 30 review. Research in Nursing and Health, 2018, 41, 173-184 Serious infection risk after 1 year between patients with rheumatoid arthritis treated with rituximab or with a second TNFi after initial TNFi failure: results from The British Society for 29 3.9 15 Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology, 2018, 57, 1533-1540 Malignancy and rheumatoid arthritis: Epidemiology, risk factors and management. Best Practice and 28 5.3 33 Research in Clinical Rheumatology, 2018, 32, 869-886 OP0229 The association of biologic drug-levels with infection risk: results from the british society 27 for rheumatology biologics register for rheumatoid arthritis 2018, Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target 26 58 2.4 approach: 1-year results of CareRA, a randomised pragmatic open-label superiority trial. Annals of Pregnancy outcomes in women with rheumatoid arthritis ever treated with rituximab. 25 3.9 4 Rheumatology, 2017, 56, 661-663 AB0995 Does Bmi Increase in Patients with Early Rheumatoid Arthritis When Treated with Short-Term Glucocorticoid Remission Induction Schemes?. Annals of the Rheumatic Diseases, 2016, 24 2.4 75, 1241.3-1242 OP0172 A Cost-Effectiveness Analysis of Different Intensive Combination Therapies for Early 23 Rheumatoid Arthritis: 1 Year Results of The Carera Trial. *Annals of the Rheumatic Diseases*, **2016**, 7<u>5</u>, 121.1-121 AB0996 Translation and Validation of The Flemish Version of The British Delay Questionnaire To Measure Help-Seeking Behaviour in Patients with Newly Onset Rheumatoid Arthritis. Annals of the 22 2.4 Rheumatic Diseases, 2016, 75, 1242.1-1242 SAT0612 Prevalence of Comorbidities in Carera Patients with Early Rheumatoid Arthritis at Disease 21 2.4 Onset. Annals of the Rheumatic Diseases, 2016, 75, 891.2-891

## (2013-2016)

20	Are illness perception and coping style associated with the delay between symptom onset and the first general practitioner consultation in early rheumatoid arthritis management? An exploratory study within the CareRA trial. <i>Scandinavian Journal of Rheumatology</i> , <b>2016</b> , 45, 171-8	1.9	15
19	A maximum difference scaling survey of barriers to intensive combination treatment strategies with glucocorticoids in early rheumatoid arthritis. <i>Clinical Rheumatology</i> , <b>2015</b> , 34, 861-9	3.9	9
18	Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial. <i>Arthritis Research and Therapy</i> , <b>2015</b> , 17, 97	5.7	32
17	The optimal combination therapy for the treatment of early rheumatoid arthritis. <i>Expert Opinion on Pharmacotherapy</i> , <b>2015</b> , 16, 1615-25	4	9
16	Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 27-34	2.4 1	82
15	SAT0351 Is Illness Perception and Coping Associated with the Patient-Related Treatment Delay in Early Rheumatoid Arthritis? An Explorative Study Within the Carera Trial. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 786.2-786	2.4	
14	THU0117 Low-Risk Patients Also Benefit from Remission Induction Treatment in Early Rheumatoid Arthritis: Week 52 Results from the Carera Trial. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 236.2-237	2.4	1
13	FRI0354 The Patient Trajectory from Symptom Onset Until Referral to a Rheumatologist. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 554.1-554	2.4	2
12	OP0180 Remission Induction with Dmard Combinations and Glucocorticoids is not Superior to Remission Induction with MTX Monotherapy and Glucocorticoids: Week 52 Results of the High-Risk Group from the Carera Trial. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 139.2-139	2.4	1
11	A general practice perspective on early rheumatoid arthritis management: A qualitative study from Flanders. <i>European Journal of General Practice</i> , <b>2015</b> , 21, 231-7	2.8	14
10	Patient experiences with intensive combination-treatment strategies with glucocorticoids for early rheumatoid arthritis. <i>Patient Education and Counseling</i> , <b>2015</b> , 98, 384-90	3.1	14
9	A detailed analysis of treatment delay from the onset of symptoms in early rheumatoid arthritis patients. <i>Scandinavian Journal of Rheumatology</i> , <b>2014</b> , 43, 1-8	1.9	33
8	Factors influencing the prescription of intensive combination treatment strategies for early rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , <b>2014</b> , 43, 265-72	1.9	16
7	The performance of matrices in daily clinical practice to predict rapid radiologic progression in patients with early RA. <i>Seminars in Arthritis and Rheumatism</i> , <b>2014</b> , 43, 627-31	5.3	13
6	OP0137-HPR Unravelling Preferred Outcomes of Disease and Treatment in Patients with Early Rheumatoid Arthritis: A Longitudinal Qualitative Interview Study. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 112.2-112	2.4	3
5	THU0121 Comparison of MTX Therapy with or without A Moderate Dose Glucocorticoid Bridging Scheme in Early Rheumatoid Arthritis Patients Lacking Classical Poor Prognostic Markers: Week 16 Results from the Randomized Multicenter Carera Trial. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 220.1	2.4 I-220	4
4	Effects: 16 Weeks Remission Induction Data from the Carera Trial. <i>Annals of the Rheumatic Diseases</i> ,	2.4	6
3	<b>2014</b> , 73, 226.2-226 THU0143 Performance of Prediction Matrices for Rapid Radiologic Progression in Daily Practice. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, A211.2-A211	2.4	

THU0144 Two Year Radiological Follow-Up of Early Rheumatoid Arthritis Patients Treated with Initial Step Up Monotherapy or Initial Step Down Therapy with Glucocorticoids, Followed by a Tight Control Approach. *Annals of the Rheumatic Diseases*, **2013**, 72, A211.3-A212

2.4 1

AB0169 Type of rheumatology practice is an important determinant of treatment delay in flanders. *Annals of the Rheumatic Diseases*, **2013**, 72, A837.2-A837

2.4